Q3 2020 13F Holders as of 30 Sep 2020
-
Type / Class
-
Debt / NOTE 3.500% 9/1
-
Market price (% of par)
-
107.56%
-
Total 13F principal
-
$215,022,000
-
Principal change
-
+$215,022,000
-
Total reported market value
-
$232,250,866
-
Number of holders
-
27
-
Value change
-
+$232,250,866
-
Number of buys
-
27
Institutional Holders of APELLIS PHARMACEUTICALS INC - NOTE 3.500% 9/1 as of Q3 2020
As of 30 Sep 2020,
APELLIS PHARMACEUTICALS INC - NOTE 3.500% 9/1 was held by
27 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$215,022,000
in principal (par value) of the bond.
The largest 10 bondholders included
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), LAZARD ASSET MANAGEMENT LLC, Shaolin Capital Management LLC, MACKAY SHIELDS LLC, WOLVERINE ASSET MANAGEMENT LLC, CAPSTONE INVESTMENT ADVISORS, LLC, LMR Partners LLP, Castle Creek Arbitrage, LLC, WELLS FARGO & COMPANY/MN, and AMERIPRISE FINANCIAL INC.
This page lists
27
institutional bondholders reporting positions
for the Q3 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.